Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0720

+2.9%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Howard Williams	1/20/2015 8:43:06 AM
	Read Replies (1) of 13111

The WallStreet Transcript Interviews Peter Culpepper, CFO, COO Tuesday January 20, 2015 Peter Culpepper, CFO and COO of Provectus, was recently interviewed by The WallStreet Transcript. In the interview, Mr. Culpepper discusses clinical development status, including a Phase 3 trial of PV-10 for melanoma and Phase 1b/2 trials of PV-10 for liver cancer and PV-10 combined with immune checkpoint blockade agents for melanoma. Mr. Culpepper also answers questions of clinical study time frames, funding, and potential partners. A reprint of the article is available at pvct.com on the Provectus website.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next